Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The molecular structure of beta-glucans play an important role in designing effective immunotherapies, according to new in-vitro and in-vivo studies by Biothera.
Subscribe to our email newsletter
The research which was conducted by Jun Yan of University of Louisville School of Medicine in Louisville, Kentucky supports another study that found that differences in yeast-derived beta-glucan structures determine their ability to bind to receptors on innate immune cells and the specific immune responses that result.
Biothera’s soluble beta-glucan is dependent on Complement Receptor binding to elicit neutrophil-mediated responses to antibody targeted cells and does not directly effect T cell activation.
Yan said these data demonstrate how different beta-glucan structures affect immunomodulatory mechanisms.
"Biothera’s ability to produce and characterize these beta-glucan compounds was critical to this research," Yan said.
Biothera Research & Development senior vice president William Grossman said as demonstrated in previous research, ‘structure matters’ to beta-glucan binding and initiation of differential immunomodulatory responses.
"Our commitment to researching the biological mechanisms underpinning the activity of our compounds will lead to even more effective pharmaceuticals and food-grade ingredients," Grossman said.